Semaglutide is an active ingredient used in several distinct prescription products. The brand, dosage form, route, and indication matter: diabetes-labeled Ozempic and Rybelsus products are not interchangeable with Wegovy products simply because they share an ingredient.
Semaglutide Products for Type 2 Diabetes: Brand, Form and Indication Differences
Semaglutide is the active ingredient in several FDA-approved prescription products, but those products are not one interchangeable item. Current U.S. labeling distinguishes products by brand, dosage form, route of administration, strength, approved indication, and dosing system.
For a patient researching a semaglutide prescription, the key question is not simply “Is this semaglutide?” It is “Which exact semaglutide product was prescribed?”
Ozempic injection
Ozempic injection is a semaglutide GLP-1 receptor agonist administered subcutaneously. Current labeling identifies it as a prescription product for adults with Type 2 diabetes, including use to improve glycemic control. The current label also includes cardiovascular-risk reduction in adults with Type 2 diabetes and established cardiovascular disease, and kidney/cardiovascular-risk reduction in adults with Type 2 diabetes and chronic kidney disease.
Current Ozempic injection labeling includes multi-dose pen presentations for 0.25/0.5 mg, 1 mg, and 2 mg doses, as well as certain single-dose prefilled-syringe presentations. The exact package and delivery device therefore matter when identifying the prescribed product.
Ozempic tablets and Rybelsus tablets
A major current-product distinction is that U.S. labeling now includes oral Ozempic tablets as well as Rybelsus tablets.
The current combined label identifies both Rybelsus and Ozempic tablets as oral semaglutide prescription products used in adults with Type 2 diabetes to improve glycemic control. The label also includes reduction of major adverse cardiovascular-event risk in adults with Type 2 diabetes who are at high risk for those events.
However, the two oral product lines use different tablet strengths:
- Rybelsus: 3 mg, 7 mg, and 14 mg tablets;
- Ozempic tablets: 1.5 mg, 4 mg, and 9 mg tablets.
The labeling explicitly states that Rybelsus and Ozempic tablets are not substitutable on a milligram-to-milligram basis. That makes an old assumption such as “all oral semaglutide is Rybelsus” inaccurate in 2026.
Wegovy injection and tablets
Wegovy is a separate semaglutide product family with different approved indications. Current U.S. labeling includes both injection and oral tablets.
Wegovy injection is labeled for chronic weight-management uses in qualifying adults and adolescents and for reduction of major adverse cardiovascular events in certain adults with established cardiovascular disease and obesity or overweight. Current labeling also includes an adult MASH indication for the injection under accelerated approval. The exact approved populations and conditions are defined in the current label.
Wegovy tablets are labeled for chronic weight management in qualifying adults and for cardiovascular-risk reduction in certain adults with established cardiovascular disease and obesity or overweight. Current DailyMed labeling lists Wegovy tablet strengths including 1.5 mg, 4 mg, 9 mg, and 25 mg across current package information.
These Wegovy indications are not the same as saying that every semaglutide product is a “weight-loss version” of Ozempic. Brand, route, formulation, indication, strength, and labeling all matter.
Same active ingredient does not mean free substitution
Semaglutide products should not be compared only by the milligram number on the package. Oral and injectable formulations have different delivery systems and labeling, and even oral semaglutide products are not necessarily mg-for-mg substitutable.
Before a prescription is filled, useful product questions include:
- Is the prescription for Ozempic injection, Ozempic tablets, Rybelsus, Wegovy injection, or Wegovy tablets?
- What route of administration is specified?
- What strength and package presentation are written on the prescription?
- Is the indication tied to Type 2 diabetes, cardiovascular-risk reduction, chronic weight management, or another FDA-approved use of that exact product?
- Does the payer cover the exact brand and formulation?
- Does the plan require prior authorization or documented eligibility for that product’s indication?
- If the product is temporarily difficult to source, does any change require a new or clarified prescription rather than an informal product swap?
Contact Valencia Town Center Pharmacy to confirm current semaglutide product availability and coverage for a specific prescription.
Cost and formulary differences
Insurance treatment of semaglutide can vary substantially by product and indication. A plan may cover one diabetes-labeled product while applying different rules to weight-management products. Formularies may also distinguish among injection and oral products or require prior authorization.
For that reason, a cash-price comparison alone may not answer the practical access question. The exact prescription, benefit design, indication, pharmacy network, and product package all affect what a patient may pay.
Safety boundary
Current semaglutide labels contain a boxed warning concerning risk of thyroid C-cell tumors observed in rodents and contraindications related to personal or family history of medullary thyroid carcinoma or MEN 2. Labels also contain product-specific warnings and precautions involving pancreatitis, gastrointestinal adverse reactions, gallbladder disease, hypersensitivity, and other risks.
Those issues are one reason product identity matters. This page is for product research, not for choosing a semaglutide product, changing routes, or converting doses.
For the broader medication index, see Type 2 Diabetes & Metabolic Medications.